Clinical Study
Sofosbuvir-Based Therapies for Patients with Hepatitis C Virus Infection: Real-World Experience in China
Table 1
Baseline demographics and biochemical characteristics of study population.
| | | SOF+DCV
N=96 | SOF+LDV
N=99 | SOF+VEL
N=31 | Total
N=226 |
| | Male, n(%) | 43 (45%) | 65 (66%) | 12 (39%) | 120 (53%) | | Age(years), Mean±SD | 46.6±14.3 | 39.6±7.8 | 42.7±15.2 | 43.4±8.3 | | Treatment history, n(%) | | | | | | Treatment naïve | 54 (56%) | 50 (51%) | 21 (68%) | 125 (55%) | | Treatment-experienced | 42 (44%) | 49 (49%) | 10 (32%) | 101 (45%) | | HCV genotype, n(%) | | | | | | 1b | 55 (57.2%) | 73 (73.7%) | 12 (38.7%) | 140 (61.9%) | | 2a | 13 (13.5%) | 0 | 6 (19.4%) | 19 (8.4%) | | 3a | 5 (5.2%) | 0 | 5 (16.1%) | 10 (4.4%) | | 3b | 7 (7.3%) | 0 | 5 (16.1%) | 12 (5.3%) | | 6a | 16 (16.7%) | 26 (26.3%) | 3 (9.7%) | 45 (19.9%) | | ALT(U/L), Mean±SD | 42.3±16.3 | 38.6±14.6 | 41.5±19.8 | 41.6±15.5 | | AST(U/L), Mean±SD | 34.3±13.5 | 33.2±12.8 | 35.6±15.2 | 34.5±13.1 | | Hemoglobin (g/L), Mean±SD | 136.2±20.2 | 128.8±31.1 | 133.2±22.5 | 133.1±30.8 | | Platelet×109/L, Mean±SD | 208.2±36.6 | 233.6±42.2 | 268.4±48.5 | 230.7±45.2 | | AFP (ng/ml), Mean±SD | 6.6±3.1 | 5.8±3.0 | 5.5±2.7 | 6.0±3.2 | | HCV RNA, log10 IU/ml, Mean±SD | 5.6±2.2 | 5.8±1.7 | 5.3±1.6 | 5.6±2.0 | | LSM (kPa), Mean±SD | 5.9±2.3 | 6.0±2.1 | 6.4±1.8 | 6.0±2.3 |
|
|
SOF, Sofosbuvir; DCV, Daclatasvir; LDV, Ledipasvir; VEL, Velpatasvir; HCV, hepatitis C virus; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AFP, alpha-fetoprotein; LSM, liver stiffness measurement.
|
